00000nam 2200000zi 4500 9.940342 CaOODSP 20240712142618 m o d f cr |n||||||||| 240709s2019 oncd o f00| 0 eng d CaOODSP eng rda CaOODSP n-cn--- H14-635/2019E-PDF What we heard report - stakeholder consultation on the naming of biologic drugs. [Ottawa] : Health Canada = Santé Canada, [2019] 1 online resource (8 pages) : chart text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Rapport « Ce que nous avons entendu » – consultation auprès des intervenants sur l’attribution de noms aux médicaments biologiques. "Health Canada and the Institute for Safe Medication Practices (ISMP) Canada conducted an online consultation on the naming of biologic drugs from January 18 to February 9, 2018. With the entry of biosimilars into the Canadian market, the number of biologic drugs sharing a nonproprietary (common) name is increasing. The objectives of the consultation were (1) to seek stakeholder views on whether Health Canada’s current approach to biologics naming is adequate or, if not, which alternate proposed option would be most appropriate to distinguish among biologics that share the same non-proprietary name, and (2) to better understand the impact of implementing each proposed option on external stakeholders"--Introduction, page 2. Biologicals Canada Public opinion. Drugs Labeling Canada Public opinion. Public opinion Canada. Canada. Health Canada, issuing body. Rapport « Ce que nous avons entendu » – consultation auprès des intervenants sur l’attribution de noms aux médicaments biologiques. (CaOODSP)9.940547 PDF 593 KB https://publications.gc.ca/collections/collection_2024/sc-hc/H14-635-2019-eng.pdf HTML N/A https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/naming-of-biologics-what-we-heard.html